Welcome to the international HTA database

Showing [23371 Records] Selected Records [0 Hits] [Clear]

Year	Source	Title
2011	NIHR Horizon Scanning Centre (NIHR HSC)	Ipilimumab (Yervoy) for prostate cancer – second line
2011	All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG)	Fentanyl (PecFent®)
2011	Agency for Healthcare Research and Quality (AHRQ)	Adjunctive devices for patients with acute coronary syndrome undergoing percutaneous coronary intervention
2011	Haute Autorite de sante (HAS)	[Transcutaneous aortic valve implantation by the transfemoral or transapical route]
2011	NIHR Health Technology Assessment programme	The clinical effectiveness and cost-effectiveness of genotyping for CYP2D6 for the management of women with breast cancer treated with tamoxifen: a systematic review
2011	Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA)	[Renal denervation in patients with essential hypertonia]
2011	Andalusian Health Technology Assessment Area (AETSA)	[Prioritization of patient decision aids]
2011	NIHR Horizon Scanning Centre (NIHR HSC)	Masitinib with gemcitabine for advanced or metastatic pancreatic cancer
2011	All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG)	Darunavir (Prezista®)
2011	Agency for Healthcare Research and Quality (AHRQ)	Effectiveness of early diagnosis, prevention, and treatment of clostridium difficile infection
2011	Scottish Health Technologies Group (SHTG)	What is the clinical and cost effectiveness of the ThinPrep imager® (HologicTM, Inc) for assisted cervical cytology compared with manual reading of liquid based cytology slides?
2011	Haute Autorite de sante (HAS)	[Assessment of glomerular filtration rate and serum creatinine levels in the diagnosis of chronic kidney disease in adults]
2011	NIHR Health Technology Assessment programme	A systematic review and economic evaluation of the use of tumour necrosis factor-alpha (TNF-a) inhibitors, adalimumab and infliximab, for Crohn's disease
2011	NIHR Health Technology Assessment programme	The clinical effectiveness and cost-effectiveness of management strategies for sciatica: systematic review and economic model
2011	NIHR Health Technology Assessment programme	Evaluating meta-ethnography: systematic analysis and synthesis of qualitative research
2011	Penn Medicine Center for Evidence-based Practice (CEP)	Tests for early diagnosis of sepsis
2011	Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA)	[Reorientation of the Austrian parent-child preventive care programme. Part I: Epidemiology - incidence of risk factors and diseases in pregnancy and early childhood]
2011	NIHR Horizon Scanning Centre (NIHR HSC)	Paclitaxel (Paclical) for epithelial ovarian cancer, fallopian tube cancer or peritoneal cancer – second or third line
2011	All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG)	Valsartan (Diovan®)
2011	Agency for Healthcare Research and Quality (AHRQ)	Second-generation antidepressants in the pharmacologic treatment of adult depression: an update of the 2007 comparative effectiveness review
2011	Scottish Health Technologies Group (SHTG)	The clinical and cost effectiveness of the use of brachytherapy to treat breast cancer
2011	Haute Autorite de sante (HAS)	[Albumin (or protein) to creatinine ratios in the diagnosis of chronic kidney disease in adults]
2011	Penn Medicine Center for Evidence-based Practice (CEP)	Guidelines for management of sepsis
2011	Belgian Health Care Knowledge Centre (KCE)	Transcatheter aortic valve implantation (TAVI): an updated health technology assessment
2011	Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA)	[Reorientation of the Austrian parent-child preventive care programme. Part II: international policies, approaches and screening strategies to "normal" and "risk experiences" during pregnancy and early childhood to school entry]
2011	NIHR Horizon Scanning Centre (NIHR HSC)	Caris Target Now™ molecular profiling service for solid malignant tumours
2011	All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG)	Filgrastim (Nivestim®)
2011	Agency for Healthcare Research and Quality (AHRQ)	Analgesics for osteoarthritis: an update of the 2006 comparative effectiveness review
2011	Scottish Health Technologies Group (SHTG)	What is the evidence base for the use of orthopaedic spinal surgery for mechanical low back pain or degenerative spondylolisthesis?
2011	Haute Autorite de sante (HAS)	[MRI-guided vacuum-assisted breast biopsy (VABB)]
2011	Penn Medicine Center for Evidence-based Practice (CEP)	Impact of retracted articles on the evidence base for hydroxyethyl starch
2011	Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA)	[Reorientation of the Austrian parent-child preventive care programme. Part III: Status quo of the financing and cost structures of parent-child services in Austria]
2011	Agency for Healthcare Research and Quality (AHRQ)	Attention deficit hyperactivity disorder: effectiveness of treatment in at-risk preschoolers; long-term effectiveness in all ages; and variability in prevalence, diagnosis, and treatment
2011	Scottish Health Technologies Group (SHTG)	The clinical and cost effectiveness of the use of brachytherapy to treat localised prostate cancer
2011	Penn Medicine Center for Evidence-based Practice (CEP)	Tunneled vs. non-tunneled catheters for acute hemodialysis
2011	Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA)	[Reorientation of the Austrian parent-child preventive care programme. Part IV: synthesis of parts 1-3, recommendations]
2011	Agency for Healthcare Research and Quality (AHRQ)	Angiotensin-converting enzyme inhibitors (ACEIs), angiotensin II receptor antagonists (ARBs), and direct renin inhibitors for treating essential hypertension: an update
2011	Scottish Health Technologies Group (SHTG)	Transcatheter aortic valve implantation (TAVI) for severe symptomatic aortic stenosis in adults. This evidence note updates evidence note 33 published in March 2011
2011	Haute Autorite de sante (HAS)	[Surgical haemostatic agents: treatments of last resort]
2011	National Institute for Health and Care Excellence (NICE)	Ambulight PDT for the treatment of non-melanoma skin cancer. NICE medical technologies guidance 6
2011	NIHR Health Technology Assessment programme	Identification of risk factors by systematic review and development of risk-adjusted models for surgical site infection
2011	Penn Medicine Center for Evidence-based Practice (CEP)	Active management and treatment of postpartum hemorrhage
2011	Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA)	Disinvestment. Overview of disinvestment experiences and challenges in selected countries
2011	NIHR Horizon Scanning Centre (NIHR HSC)	Dalcetrapib for the prevention of cardiovascular events
2011	Scottish Health Technologies Group (SHTG)	The clinical and cost effectiveness of long-term ventricular assist devices (VADs) as a bridge-to-transplant in adults
2011	Haute Autorite de sante (HAS)	[Biology of haemostasis disorders: bleeding time]
2011	National Institute for Health and Care Excellence (NICE)	The MIST Therapy system for the promotion of wound healing. NICE medical technologies guidance 5
2011	NIHR Health Technology Assessment programme	A randomised controlled trial of post-operative radiotherapy following breast-conserving surgery in a minimum-risk population. Quality of life at 5 years in the PRIME trial
2011	Penn Medicine Center for Evidence-based Practice (CEP)	Risk factors for hospital readmission
2011	HAYES, Inc.	Acticoat (Smith&Nephew Inc.) for Burn Wounds
2011	Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA)	Eribulin (Halaven) as third- or late- line mono-therapy for advanced/metastatic breast cancer
2011	NIHR Horizon Scanning Centre (NIHR HSC)	Edoxaban tosylate for prevention of stroke and systemic embolic events in non-valvular atrial fibrillation
2011	Scottish Health Technologies Group (SHTG)	Is radiofrequency ablation treatment a clinically and cost effective treatment to be offered to people with renal cancer in NHSScotland?
2011	Haute Autorite de sante (HAS)	[Biology of haemostasis disorders: thrombin time]
2011	Penn Medicine Center for Evidence-based Practice (CEP)	Femoral closure devices for cardiac catheterization
2011	Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA)	[Sacral nerve stimulation for fecal incontinence]
2011	NIHR Horizon Scanning Centre (NIHR HSC)	HHLivC (Human Heterologous Liver Cells) for urea cycle disorders
2011	Haute Autorite de sante (HAS)	[Biology of haemostasis disorders: photometric platelet aggregation test]
2011	Penn Medicine Center for Evidence-based Practice (CEP)	Transradial access for cardiac catheterization
2011	HAYES, Inc.	Antibacterial suture for prevention of infection
2011	Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA)	[Percutaneuous left atrial appendage closure for the prevention of thrombo-embolic events in patients with atrial fibrillation]
2011	Haute Autorite de sante (HAS)	[Biology of haemostasis disorders: testing for antibodies to platelet factor 4 in a patient with heparin – induced thrombocytopenia]
2011	Penn Medicine Center for Evidence-based Practice (CEP)	Guidelines for verifying Dobbhoff tube placement
2011	Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA)	[Mechanical percutaneous transluminal cerebral clot retrieval in acute ischemic stroke]
2011	NIHR Horizon Scanning Centre (NIHR HSC)	IRay™ for wet age related macular degeneration
2011	Haute Autorite de sante (HAS)	[Biology of haemostasis disorders: detection and titration of antihaemophilic factor (AHF) inhibitor]
2011	Finnish Office for Health Care Technology Assessment (Finohta)	[Azacitidine in the treatment of high-risk myelodysplastic syndrome]
2011	The Swedish Council on Health Technology Assessment (SBU)	[Percutaneous vertebroplasty and balloon kyphoplasty in treating painful osteoporotic vertebral compression fractures]
2011	Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA)	Selective internal radiation therapy using yttrium-90 microspheres for the treatment of primary or metastatic liver malignancies
2011	NIHR Horizon Scanning Centre (NIHR HSC)	Erlotinib (Tarceva) in combination with sorafenib (Nexavar) for unresectable, advanced or metastatic hepatocellular carcinoma – first line
2011	Haute Autorite de sante (HAS)	[Biology of haemostasis disorders: lupus anticoagulant detection]
2011	HAYES, Inc.	Bipolar plasmakinetic electrovaporization for benign prostatic hyperplasia (BPH)
2011	Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA)	[Percutaneous aortic valve replacement with a side note to hybrid operating rooms]
2011	NIHR Horizon Scanning Centre (NIHR HSC)	ThromboLUX™ for determining platelet quality
2011	Haute Autorite de sante (HAS)	[Biology of haemostasis disorders: testing for the G1691A mutation of the factor V gene (Leiden FV) and the G20210A mutation of the factor II gene]
2011	The Netherlands Organisation for Health Research and Development (ZonMw)	[Validation of the 'Trimbos and iMTA questionnaire on costs associated with psychiatric illness' (TiC-P) for measuring health care utilisation and production loss]
2011	NIHR Health Technology Assessment programme	Diagnostic management strategies for adults and children with minor head injury: a systematic review and an economic evaluation
2011	Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA)	Anti-Vascular-Endothelial-Growth-Factor (anti-VEGF) for the treatment of diabetic macular edema
2011	Catalan Agency for Health Information, Assessment and Quality (CAHIAQ -formerly CAHTA)	[Validation of the FRAX fracture assessment risk tool]
2011	NIHR Horizon Scanning Centre (NIHR HSC)	Rituximab (MabThera) for anti-neutrophil cytoplasmic antibody (ANCA) associated vasculitis
2011	Haute Autorite de sante (HAS)	[Biology of haemostasis abnormalities – summary]
2011	NIHR Health Technology Assessment programme	The value of FDG positron emission tomography/computerised tomography (PET/CT) in pre-operative staging of colorectal cancer: a systematic review and economic evaluation
2011	Adelaide Health Technology Assessment (AHTA)	Prevention, identification and management of foot complications in diabetes: technical report
2011	NIHR Horizon Scanning Centre (NIHR HSC)	Odanacatib for post-menopausal osteoporosis – first or second line
2011	NIHR Health Technology Assessment programme	Lapatinib and trastuzumab in combination with an aromatase inhibitor for the first-line treatment of metastatic hormone receptor-positive breast cancer which over-expresses human epidermal growth factor 2 (HER2): a systematic review and economic analysis
2011	Norwegian Knowledge Centre for the Health Services (NOKC)	Thromboprophylactic treatment with rivaroxaban or dabigatran compared with enoxaparin or dalteparin in patients undergoing elective hip- or knee replacement surgery
2011	NIHR Horizon Scanning Centre (NIHR HSC)	Tocilizumab (RoACTEMRA) for early rheumatoid arthritis not treated with methotrexate – first line
2011	Haute Autorite de sante (HAS)	[Selection of iron metabolism tests in cases where iron deficiency is suspected]
2011	NIHR Horizon Scanning Centre (NIHR HSC)	VEGF trap-eye (Eylea) for macular oedema secondary to central retinal vein occlusion - first line
2011	Haute Autorite de sante (HAS)	[Self-monitoring of blood glucose in type 2 diabetes: limited use for a target population]
2011	NIHR Health Technology Assessment programme	Bone-anchored hearing aids (BAHAs) for people who are bilaterally deaf: a systematic review and economic evaluation
2011	HAYES, Inc.	Endoscopic cyclophotocoagulation for glaucoma
2011	NIHR Horizon Scanning Centre (NIHR HSC)	Trabectedin (Yondelis) for advanced and/or metastatic translocation-related sarcomas - first line
2011	NIHR Horizon Scanning Centre (NIHR HSC)	Dimethyl fumarate for relapsing-remitting multiple sclerosis
2011	NIHR Horizon Scanning Centre (NIHR HSC)	Olesoxime for amyotrophic lateral sclerosis - first line
2011	NIHR Horizon Scanning Centre (NIHR HSC)	Lacosamide (Vimpat) for epilepsy – first and second line
2011	NIHR Health Technology Assessment programme	Evaluation of patient reporting of adverse drug reactions to the UK 'Yellow Card Scheme': literature review, descriptive and qualitative analyses, and questionnaire surveys
2011	NIHR Horizon Scanning Centre (NIHR HSC)	Adalimumab (Humira) for axial spondyloarthritis - second line
2011	NIHR Horizon Scanning Centre (NIHR HSC)	Liraglutide (Victoza) in combination with basal insulin for type 2 diabetes
2011	NIHR Horizon Scanning Centre (NIHR HSC)	Eslicarbazepine acetate (Zebinix) for partial onset seizures in epilepsy - monotherapy